Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2

被引：8

作者：

Ashton, Kate S. ^{[1
]}

St Jean, David J., Jr. ^{[1
]}

Poon, Steve F. ^{[1
]}

Lee, Matthew R. ^{[1
]}

Allen, John G. ^{[1
]}

Zhang, Shiwen ^{[2
]}

Lofgren, Julie A. ^{[2
]}

Zhang, Xiaoling ^{[2
]}

Fotsch, Christopher ^{[1
]}

Hungate, Randall ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

[2] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 18期

关键词：

PKB; AKT; CDK; Cancer; PROTEIN-KINASE-B; PI3K/AKT PATHWAY; RECENT PROGRESS; CANCER; IDENTIFICATION; DISCOVERY; BINDING; AKT/PKB; TUMORIGENESIS;

D O I：

10.1016/j.bmcl.2011.07.056

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Through the analysis of X-ray crystallographic information and previous SAR studies, a novel series of protein kinase B (PKB/AKT) inhibitors was developed. The compounds showed nanomolar inhibition of AKT1 and were selective against cyclin-dependent kinase 2 (CDK2). (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：5191 / 5196

页数：6

共 19 条

[11] Identification of a proline-rich Akt substrate as a 14-3-3 binding partner
Kovacina, KS
Park, GY
Bae, SS
Guzzetta, AW
Schaefer, E
Birnbaum, MJ
Roth, RA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) : 10189 - 10194
[12] Recent progress in the discovery of Akt inhibitors as anticancer agents
Li, Qun
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (09) : 1077 - 1130
[13] The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
Lindsley, Craig W.
Barnett, Stanley F.
Layton, Mark E.
Bilodeau, Mark T.
[J]. CURRENT CANCER DRUG TARGETS, 2008, 8 (01) : 7 - 18
[14] Synthesis and structure based optimization of novel Akt inhibitors
Lippa, Blaise
Pan, Gonghua
Corbett, Matthew
Li, Chao
Kauffman, Goss S.
Pandit, Jayvardhan
Robinson, Shaughnessy
Wei, Liuqing
Kozina, Ekaterina
Marr, Eric S.
Borzillo, Gary
Knauth, Elisabeth
Barbacci-Tobin, Elsa G.
Vincent, Patrick
Troutman, Merin
Baker, Deborah
Rajamohan, Francis
Kakar, Shefali
Clark, Tracey
Morris, Joel
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (11) : 3359 - 3363
[15] Identification of inhibitors of protein kinase B using fragment-based lead discovery
Saxty, Gordon
Woodhead, Steven J.
Berdini, Valerio
Davies, Thomas G.
Verdonk, Marcel L.
Wyatt, Paul G.
Boyle, Robert G.
Barford, David
Downham, Robert
Garrett, Michelle D.
Carr, Robin A.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) : 2293 - 2296
[16] Commentary - AKT plays a central role in tumorigenesis
Testa, JR
Bellacosa, A
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) : 10983 - 10985
[17] 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics
Zeng, Qingping
Bourbeau, Matthew P.
Wohlhieter, G. Erich
Yao, Guomin
Monenschein, Holger
Rider, James T.
Lee, Matthew R.
Zhang, Shiwen
Lofgren, Julie
Freeman, Daniel
Li, Chun
Tominey, Elizabeth
Huang, Xin
Hoffman, Douglas
Yamane, Harvey
Tasker, Andrew S.
Dominguez, Celia
Viswanadhan, Vellarkad N.
Hungate, Randall
Zhang, Xiaoling
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1652 - 1656
[18] Azole-based inhibitors of AKT/PKB for the treatment of cancer
Zeng, Qingping
Allen, John G.
Bourbeau, Matthew P.
Wang, Xianghong
Yao, Guomin
Tadesse, Seifu
Rider, James T.
Yuan, Chester C.
Hong, Fang-Tsao
Lee, Matthew R.
Zhang, Shiwen
Lofgren, Julie A.
Freeman, Daniel J.
Yang, Suijin
Li, Chun
Tominey, Elizabeth
Huang, Xin
Hoffman, Douglas
Yamane, Harvey K.
Fotsch, Christopher
Dominguez, Celia
Hungate, Randall
Zhang, Xiaoling
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1559 - 1564
[19] Kinetic mechanism of AKT/PKB enzyme family
Zhang, Xiaoling
Zhang, Shiwen
Yamane, Harvey
Wahl, Robert
Ali, Arisha
Lofgren, Julie A.
Kendall, Richard L.
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (20) : 13949 - 13956

← 1 2 →